Synergistic effect of immunoregulatory cytokines on peripheral blood monocytes from patients with inflammatory bowel disease.
Active inflammatory bowel disease (IBD) is characterized by increased monocyte secretion of proinflammatory cytokines. Immunoregulatory cytokines such as Interleukin (IL)-4, IL-10, and IL-13 are capable of inhibiting the proinflammatory cytokine response of activated monocytes. The aim of our study was to determine the effect of different antiinflammatory cytokines under various culture conditions and to evaluate combinations of antiinflammatory cytokines in down-regulating monocyte response in IBD. Peripheral monocytes from patients with active IBD were isolated and stimulated with pokeweed mitogen (PWM). IL-4, IL-10, IL-13 and a combination of IL-4/IL-10 and IL-10/IL-13 were added at different concentrations and different times. Secretion of IL-1beta and TNF-alpha was assessed using sandwich ELISA systems. There was a diminished down-regulation of TNF-alpha by IL-4 and IL-13 in IBD when the cytokines were added at the time of stimulation, while there was a significantly higher down-regulation when monocytes were primed with these Th-2 cytokines 24 hr before activation. IL-10 plus IL-4 and IL-10 plus IL-13, respectively, inhibited the proinflammatory cytokine response of monocytes as well as matured macrophages much more than IL-4, IL-10, or IL-13 alone. Even at suboptimal concentrations for each cytokine alone, a combination of cytokines showed synergistic inhibitory effects. In summary, a combination of antiinflammatory cytokines is more effective in down-regulating the response of activated monocytes than using the cytokines alone and thus may have a potential therapeutic benefit for patients with IBD.
Kucharzik
T
T
Department of Medicine B, University of Münster, Germany.
Lügering
N
N
Adolf
M
M
Domschke
W
W
Stoll
R
R
D002478:Cells, Cultured; D003093:Colitis, Ulcerative / Q000378:metabolism* / Q000503:physiopathology; D003424:Crohn Disease / Q000378:metabolism* / Q000503:physiopathology; D015536:Down-Regulation; D006801:Humans; D066298:In Vitro Techniques; D007249:Inflammation / Q000378:metabolism; D007375:Interleukin-1 / Q000096:biosynthesis*; D016753:Interleukin-10 / Q000008:administration & dosage / Q000494:pharmacology / Q000502:physiology; D018793:Interleukin-13 / Q000008:administration & dosage / Q000494:pharmacology / Q000502:physiology; D015847:Interleukin-4 / Q000008:administration & dosage / Q000494:pharmacology / Q000502:physiology; D007378:Interleukins / Q000008:administration & dosage / Q000494:pharmacology* / Q000502:physiology; D009000:Monocytes / Q000276:immunology / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
D007375:Interleukin-1; D018793:Interleukin-13; D007378:Interleukins; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D015847:Interleukin-4